Kobe iPSC-Derived T Cells Shrink Solid Tumours in Mice

Researchers at Kobe University have developed off-the-shelf, mass-producible γδ T cells derived from induced pluripotent stem cells (iPSCs) that shrank patient-derived colorectal tumours engrafted into mice by 43-92%. Published in Stem Cell Reports on 23 July 2026, the preclinical study represents an important step toward affordable, allogeneic cell therapy for solid tumours, one of the most persistently difficult indications in the cancer immunotherapy space.

Standard cell therapy approaches require the extraction of a patient’s own T cells from blood, modifying them in the lab and reintroducing them, an expensive and time-consuming process. Gamma-delta (γδ) T cells, a subclass that can be harvested from a donor and used across patients, sidestep the personalisation problem but are naturally scarce and difficult to multiply. Led by stem cell researcher Aoi Takashi, the Kobe team addressed this by creating iPS cells from cancer-specific γδ T cells and converting them back into functional T cells on demand, achieving an 80,000-fold multiplication without any animal cells or extracts.

The resulting T cells were tested against patient-derived colorectal cancer tumours implanted in mice. Even when administered intravenously a week after tumour implantation (simulating a systemic therapy setting against metastasising disease), tumour weights decreased between 43% and 92% across the three mice tested. First author Ryoko Futai emphasised the value of using patient-derived organoids over cell culture lines, given the drug insensitivities and physical barriers actual tumours present. The team cautioned that the work remains preclinical, based on only three to four mice per experiment and two patient-derived tumour models.

The commercial signal is a growing intersection between iPS-derived cell therapy platforms and off-the-shelf allogeneic cancer treatment, at a moment when solid tumour cell therapy remains largely unsolved. If the approach scales, the Kobe workflow could position Japanese biotech alongside Fate Therapeutics, Century Therapeutics and Sana Biotechnology in the off-the-shelf CAR-T and γδ T cell competitive landscape.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!